Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

The target landscape of clinical kinase drugs.

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner R, Hahne H, Tõnisson N, Kramer K, Götze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif PA, Schneider S, Felder ER, Ruland J, Médard G, Jeremias I, Spiekermann K, Kuster B.

Science. 2017 Dec 1;358(6367). pii: eaan4368. doi: 10.1126/science.aan4368.

PMID:
29191878
2.

Pharmacoproteomic characterisation of human colon and rectal cancer.

Frejno M, Zenezini Chiozzi R, Wilhelm M, Koch H, Zheng R, Klaeger S, Ruprecht B, Meng C, Kramer K, Jarzab A, Heinzlmeir S, Johnstone E, Domingo E, Kerr D, Jesinghaus M, Slotta-Huspenina J, Weichert W, Knapp S, Feller SM, Kuster B.

Mol Syst Biol. 2017 Nov 3;13(11):951. doi: 10.15252/msb.20177701.

3.

Chemoproteomics-Aided Medicinal Chemistry for the Discovery of EPHA2 Inhibitors.

Heinzlmeir S, Lohse J, Treiber T, Kudlinzki D, Linhard V, Gande SL, Sreeramulu S, Saxena K, Liu X, Wilhelm M, Schwalbe H, Kuster B, Médard G.

ChemMedChem. 2017 Jun 21;12(12):999-1011. doi: 10.1002/cmdc.201700217. Epub 2017 Jun 12.

PMID:
28544567
4.

Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs.

Heinzlmeir S, Kudlinzki D, Sreeramulu S, Klaeger S, Gande SL, Linhard V, Wilhelm M, Qiao H, Helm D, Ruprecht B, Saxena K, Médard G, Schwalbe H, Kuster B.

ACS Chem Biol. 2016 Dec 16;11(12):3400-3411. Epub 2016 Nov 7.

PMID:
27768280
5.

Expression and Purification of EPHA2 Tyrosine Kinase Domain for Crystallographic and NMR Studies.

Gande SL, Saxena K, Sreeramulu S, Linhard V, Kudlinzki D, Heinzlmeir S, Reichert AJ, Skerra A, Kuster B, Schwalbe H.

Chembiochem. 2016 Dec 2;17(23):2257-2263. doi: 10.1002/cbic.201600483. Epub 2016 Nov 9.

PMID:
27685543
6.

Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).

Ostrovskyi D, Rumpf T, Eib J, Lumbroso A, Slynko I, Klaeger S, Heinzlmeir S, Forster M, Gehringer M, Pfaffenrot E, Bauer SM, Schmidtkunz K, Wenzler S, Metzger E, Kuster B, Laufer S, Schüle R, Sippl W, Breit B, Jung M.

Future Med Chem. 2016 Sep;8(13):1537-51. doi: 10.4155/fmc-2016-0132. Epub 2016 Aug 30.

PMID:
27572962
7.

Identification of Highly Potent Protein Kinase C-Related Kinase 1 Inhibitors by Virtual Screening, Binding Free Energy Rescoring, and in vitro Testing.

Slynko I, Schmidtkunz K, Rumpf T, Klaeger S, Heinzlmeir S, Najar A, Metzger E, Kuster B, Schüle R, Jung M, Sippl W.

ChemMedChem. 2016 Sep 20;11(18):2084-94. doi: 10.1002/cmdc.201600284. Epub 2016 Jul 29.

PMID:
27472906
8.

Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors.

Klaeger S, Gohlke B, Perrin J, Gupta V, Heinzlmeir S, Helm D, Qiao H, Bergamini G, Handa H, Savitski MM, Bantscheff M, Médard G, Preissner R, Kuster B.

ACS Chem Biol. 2016 May 20;11(5):1245-54. doi: 10.1021/acschembio.5b01063. Epub 2016 Feb 25.

PMID:
26863403
9.

Evaluation of Kinase Activity Profiling Using Chemical Proteomics.

Ruprecht B, Zecha J, Heinzlmeir S, Médard G, Lemeer S, Kuster B.

ACS Chem Biol. 2015 Dec 18;10(12):2743-52. doi: 10.1021/acschembio.5b00616. Epub 2015 Oct 5.

PMID:
26378887
10.

DENEDDYLASE1 deconjugates NEDD8 from non-cullin protein substrates in Arabidopsis thaliana.

Mergner J, Heinzlmeir S, Kuster B, Schwechheimer C.

Plant Cell. 2015 Mar;27(3):741-53. doi: 10.1105/tpc.114.135996. Epub 2015 Mar 17.

11.

Optimized chemical proteomics assay for kinase inhibitor profiling.

Médard G, Pachl F, Ruprecht B, Klaeger S, Heinzlmeir S, Helm D, Qiao H, Ku X, Wilhelm M, Kuehne T, Wu Z, Dittmann A, Hopf C, Kramer K, Kuster B.

J Proteome Res. 2015 Mar 6;14(3):1574-86. doi: 10.1021/pr5012608. Epub 2015 Feb 20.

PMID:
25660469
12.

Probing SH2-domains using Inhibitor Affinity Purification (IAP).

Höfener M, Heinzlmeir S, Kuster B, Sewald N.

Proteome Sci. 2014 Jul 16;12:41. doi: 10.1186/1477-5956-12-41. eCollection 2014.

13.

New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics.

Ku X, Heinzlmeir S, Helm D, Médard G, Kuster B.

J Proteome Res. 2014 May 2;13(5):2445-52. doi: 10.1021/pr401247t. Epub 2014 Apr 22.

PMID:
24712744
14.

A new chemical probe for quantitative proteomic profiling of fibroblast growth factor receptor and its inhibitors.

Ku X, Heinzlmeir S, Liu X, Médard G, Kuster B.

J Proteomics. 2014 Jan 16;96:44-55. doi: 10.1016/j.jprot.2013.10.031. Epub 2013 Oct 31.

PMID:
24184958
15.

ML3 is a NEDD8- and ubiquitin-modified protein.

Hakenjos JP, Bejai S, Ranftl Q, Behringer C, Vlot AC, Absmanner B, Hammes U, Heinzlmeir S, Kuster B, Schwechheimer C.

Plant Physiol. 2013 Sep;163(1):135-49. doi: 10.1104/pp.113.221341. Epub 2013 Jul 31.

Supplemental Content

Loading ...
Support Center